PD‑L1 Lung (Atezolizumab), IHC
Also known as: PDL1, VENTANA® PD-L1 (SP142) Assay, SP142 (Ventana)
Use
Determining PD‑L1 expression in non‑small cell lung cancer (NSCLC) tissue can provide insight into the potential survival benefit from treatment with TECENTRIQ (atezolizumab). Specifically, PD‑L1 expression in ≥50% of tumor cells or ≥10% of tumor‑infiltrating immune cells as determined by this assay may correlate with enhanced overall survival from treatment with atezolizumab.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin‑fixed, paraffin‑embedded tissue block, or minimum 5 unstained positively charged slides
Collection Instructions
Submit FFPE block or minimum 5 unstained positively charged slides in IHC specimen transport kit
Causes for Rejection
Baked or melted slides; previously stained slides; cytospins; tissue types other than lung cancer specimens; cytology cell block; decalcified specimens; fixatives other than formalin
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Tissue block: 5 years; Slides: 30 days |
| Refrigerated | Tissue block: 5 years; Slides: 30 days |
| Frozen | Unacceptable for both |